Exhibit 99.1

AgeX Therapeutics Reports Fourth Quarter and Annual 2018 Financial Results and Provides Business Update

  • Ends 2018 with triad of innovative cell therapy technologies: UniverCyte™ for immune tolerance, PureStem® for cell derivation and manufacturing, and HyStem® for cell delivery
  • Potential to generate any human cell type with clinical and commercial friendly characteristics of hypoimmunogenicity, low COGS and availability off-the-shelf
  • Juvenescence increased ownership by paying BioTime, Inc. $43.2M to become largest shareholder
  • Became public company with common stock traded on the NYSE American under ticker “AGE”
  • Board and management strengthened with seasoned professionals in financing, R&D and cell therapies
  • Secured almost $10M from sale of a non-core asset, equity financing and NIH Grant

ALAMEDA, Calif.--(BUSINESS WIRE)--April 1, 2019--AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative cellular and regenerative therapeutics for diseases of old age, reported financial and operating results for the fourth quarter and year ended December 31, 2018.

“2018 has been a transformative year for AgeX. We became a public company, listed on the NYSE American, and made progress toward becoming a leader in the cell therapy and longevity sectors,” said Michael D. West, Ph.D., Chief Executive Officer. “One highlight was that we acquired an immune tolerance technology, UniverCyte™, with the potential to produce hypoimmunogenic cells for new therapies. Considering the number of high-profile publications and deals in this space, we would expect this platform to hold us in good stead for both our current product development programs and the potential for third party collaborations. We think this technology could help us deliver nearer and longer term value to our stockholders.”

“AgeX has both exciting cell- and iTR™-based platforms. Using UniverCyte™ in combination with our pluripotent stem cell-based PureStem® cell derivation and manufacturing technology, we aim to generate universal, off-the-shelf cells for therapeutic products with reduced COGS,” said Greg Bailey, M.D., Chairman of the AgeX Board of Directors. “Our goal is to overcome key industry barriers to successful development and commercialization of cellular therapies, including immune rejection, high manufacturing costs, and a service-based business model.”


The following information was filed by Agex Therapeutics, Inc. (AGE) on Monday, April 1, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Agex Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Agex Therapeutics, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account